WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a
biopharmaceutical company that develops anticancer therapeutics using
its antibody expertise and Targeted Antibody Payload (TAP) technology,
today announced that the following presentations by Company management
at upcoming investor conferences will be webcast:
-
Lazard Capital Markets 9th Annual
Healthcare Conference
3:00 pm ET on November 14, 2012 in New
York, NY
Presenter: Gregory Perry, Executive Vice President and
CFO
-
Jefferies 2012 Global Healthcare Conference in London
10:00
am GMT (5:00 am ET) on November 15, 2012 in London, England
Presenter:
Daniel Junius, President and CEO
A webcast of each presentation can be accessed live through the
"Investor Information" section of the Company's website, www.immunogen.com;
a replay of each presentation will be available at the same location for
one week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The Company's TAP
technology uses monoclonal antibodies to deliver one of ImmunoGen's
proprietary cancer-killing agents specifically to tumor cells. There are
now ten TAP compounds in clinical development, of which three are wholly
owned by the Company. ImmunoGen's collaborative partners include Amgen,
Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and Sanofi. Marketing
applications for trastuzumab emtansine (T-DM1), the most advanced
compound using ImmunoGen's TAP technology, have been submitted in the US
and Europe. Roche is developing this compound under an agreement between
ImmunoGen and Genentech, a member of the Roche Group. More information
about ImmunoGen can be found at www.immunogen.com.
Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
Source: ImmunoGen, Inc.
News Provided by Acquire Media